Having lost a great deal of weight appears to offer some protection against ill health even for those who have regained some of their weight loss.
FDA greenlights Incyte and Syndax’s GvHD drug Niktimvo
The FDA approval for Incyte and Syndax’s Nikitimvo was based on the positive data from the Phase II AGAVE-201 trial. Image Credit: JHVEPhoto / Shutterstock.